Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission
Por:
Diaz-Beya, M, Labopin, M, Maertens, J, Alijurf, M, Passweg, J, Dietrich, B, Schouten, H, Socie, G, Schaap, N, Schwerdtfeger, R, Volin, L, Michallet, M, Polge, E, Sierra, J, Mohty, M, Esteve, J, Nagler, A, European Soc Blood Marrow
Publicada:
1 jun 2020
Ahead of Print:
1 feb 2020
Resumen:
Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0 center dot 001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.
Filiaciones:
Diaz-Beya, M:
Hosp Clin Barcelona, Dept Hematol, Villarroel 170, E-08036 Barcelona, Spain
Josep Carreras Leukemia Res Inst, IDIBAPS, Barcelona, Spain
Labopin, M:
Hop St Antoine, EBMT Paris Study Off, Dept Hematol & Cell Therapy, Paris, France
Maertens, J:
Univ Hosp Gasthuisberg, Leuven, Belgium
Alijurf, M:
King Faisal Specialist Hosp & Res Ctr Oncol, Riyadh, Saudi Arabia
Passweg, J:
Univ Hosp Hematol, Basel, Switzerland
Dietrich, B:
Univ Hosp, Dept Bone Marrow Transplantat, Essen, Germany
Schouten, H:
Univ Hosp, Dept Internal Med, Hematol Oncol, Maastricht, Netherlands
Socie, G:
Hosp St Louis, Div Hematol, Paris, France
Univ Paris, Paris, France
Schaap, N:
Radbud Univ, Med Ctr, Nijmegen, Netherlands
Schwerdtfeger, R:
Diagnost Helios Klin, Deutsch Klin, Ctr Hematopoiet Cell Transplantat, Wiesbaden, Germany
Volin, L:
Helsinki Univ Hosp, Ctr Comprehens Canc, Stem Cell Transplantat Unit, Helsinki, Finland
Michallet, M:
Hop Edouard Herriot, Lyon, France
Polge, E:
Hop St Antoine, EBMT Paris Study Off, Dept Hematol & Cell Therapy, Paris, France
Sierra, J:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, IIB St Pau, Dept Hematol, Barcelona, Spain
Autonomous Univ Barcelona, Josep Carreras Leukemia Res Inst, Barcelona, Spain
Mohty, M:
Hop St Antoine, EBMT Paris Study Off, Dept Hematol & Cell Therapy, Paris, France
Hosp St Antoine, Dept Hematol, Paris, France
Esteve, J:
Hosp Clin Barcelona, Dept Hematol, Villarroel 170, E-08036 Barcelona, Spain
Josep Carreras Leukemia Res Inst, IDIBAPS, Barcelona, Spain
Univ Barcelona, Dept Med, Barcelona, Spain
Nagler, A:
Hop St Antoine, EBMT Paris Study Off, Dept Hematol & Cell Therapy, Paris, France
Chaim Sheba Med Ctr, Div Hematol, Tel Hashomer, Israel
|